天津医科大学学报
天津醫科大學學報
천진의과대학학보
Journal of Tianjin Medical University
2015年
6期
484-487
,共4页
罗格列酮%糖尿病%大鼠%Chemerin-CMKLR1%基因表达
囉格列酮%糖尿病%大鼠%Chemerin-CMKLR1%基因錶達
라격렬동%당뇨병%대서%Chemerin-CMKLR1%기인표체
rosiglitazone%diabetes%rat%Chemerin-CMKLR1%gene expression
目的：通过检测罗格列酮干预后CMKLR1及Chemerin在自发性2型糖尿病大鼠脂肪组织中表达水平，探讨Chemerin-CMKLR1通路在肥胖、胰岛素抵抗及2型糖尿病发病机制中的作用。方法：4周龄大鼠30只，经相关实验至30周证实造模成功2型糖尿病大鼠20只，再随机分为罗格列酮干预组和模型组各10只，进行相关实验室指标检测，以实时荧光定量法检测脂肪组织CMKLR1及Chemerin基因的表达水平。结果：罗格列酮干预后大鼠各实验室指标明显改善，干预组大鼠网膜组织CMKLR1的表达明显低于模型组（P<0.01），干预后网膜及皮下脂肪组织中Chemerin的表达明显低于模型组（P<0.01）。罗格列酮干预后网膜脂肪细胞平均最大直径明显缩小（P<0.01），而皮下脂肪细胞平均最大直径无明显变化（P>0.05）。结论：Chemerin-CMKLR1通路成为治疗肥胖、胰岛素抵抗和2型糖尿病的新靶点。
目的：通過檢測囉格列酮榦預後CMKLR1及Chemerin在自髮性2型糖尿病大鼠脂肪組織中錶達水平，探討Chemerin-CMKLR1通路在肥胖、胰島素牴抗及2型糖尿病髮病機製中的作用。方法：4週齡大鼠30隻，經相關實驗至30週證實造模成功2型糖尿病大鼠20隻，再隨機分為囉格列酮榦預組和模型組各10隻，進行相關實驗室指標檢測，以實時熒光定量法檢測脂肪組織CMKLR1及Chemerin基因的錶達水平。結果：囉格列酮榦預後大鼠各實驗室指標明顯改善，榦預組大鼠網膜組織CMKLR1的錶達明顯低于模型組（P<0.01），榦預後網膜及皮下脂肪組織中Chemerin的錶達明顯低于模型組（P<0.01）。囉格列酮榦預後網膜脂肪細胞平均最大直徑明顯縮小（P<0.01），而皮下脂肪細胞平均最大直徑無明顯變化（P>0.05）。結論：Chemerin-CMKLR1通路成為治療肥胖、胰島素牴抗和2型糖尿病的新靶點。
목적：통과검측라격렬동간예후CMKLR1급Chemerin재자발성2형당뇨병대서지방조직중표체수평，탐토Chemerin-CMKLR1통로재비반、이도소저항급2형당뇨병발병궤제중적작용。방법：4주령대서30지，경상관실험지30주증실조모성공2형당뇨병대서20지，재수궤분위라격렬동간예조화모형조각10지，진행상관실험실지표검측，이실시형광정량법검측지방조직CMKLR1급Chemerin기인적표체수평。결과：라격렬동간예후대서각실험실지표명현개선，간예조대서망막조직CMKLR1적표체명현저우모형조（P<0.01），간예후망막급피하지방조직중Chemerin적표체명현저우모형조（P<0.01）。라격렬동간예후망막지방세포평균최대직경명현축소（P<0.01），이피하지방세포평균최대직경무명현변화（P>0.05）。결론：Chemerin-CMKLR1통로성위치료비반、이도소저항화2형당뇨병적신파점。
Objective:To investigate the expression of CMKLR1 and Chemerin mRNA in subcutaneous and visceral adipose tissue of rats and discuss the intervention of Chemerin-CMKLR1 to involve in the pathogenesis of obesity, insulin resistance and type 2 diabetes. Methods:Thirty male rats of 4 weeks were selected. Twenty rats were proved with diabetes through experimental methods after 30 weeks. Models were separated into rosiglitazone group and diabetes group with ten rats in each group. Experiment dates were detected. The mRNA levels of CMKLR1 and Chemerin in adipose tissue were detected by real-time PCR. Results:Experiments dates were improved after the intervention of rosiglitazone. The mRNA levels of CMKLR1 in visceral adipose tissue of rats in rosiglitazone group were lower than those in diabetes group (P<0.01).The mRNA levels of Chemerin of subcutaneous and visceral adipose tissue of rats in rosiglitazone group were lower than those in diabetes group (P<0.01). Maximum diameter in visceral adipocyte in rosiglitazone group decreased compared with that in diabetes group (P<0.01). Maximum diameter was no difference in subcutaneous tissue between two groups (P>0.05). Conclusion:The intervention of the expression of CMKLR1 and Chemerin mRNA become new treatment target of obesity and insulin resistance and type 2 diabetes by rosiglitazone.
